Michael D. Lockshin, MD

Appointments

Senior Clinical Investigator, Hospital for Special Surgery

Professor of Medicine and OB-GYN, Weill Medical College of Cornell University

Director, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery

Co-Director, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery

 

Michael D. Lockshin, MD is the author of the following articles on HSS.edu:

Selected Publications

Boumpas DT, Austin HA III, Fessler BJ, Balow JE, Klippel JH, Lockshin MD: Systemic lupus erythematosus: emerging concepts. Part II. Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 123: 42-53, 1995

Buyon JP, Nelson JL, Lockshin MD. The effects of pregnancy on autoimmune diseases. Clin Immunol Immunopathol, 78:99-104, 1996

Lockshin, MD. Pathogenesis of the antiphospholipid antibody syndrome. Lupus 5:404-408, 1996

Lockshin, MD. Antiphospholipid Antibody: babies, blood clots, biology. Grand Rounds at the Clinical Center of the National Institutes of Health. JAMA 277:1549-51,1997.

Lockshin, MD. Why women? Lupus 6:625-632, 1997

Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus: a case-control study, N Engl J Med 2003;349:2399-2406

Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M; On behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004 Feb; 65(2): 521-530.

ACR Ad Hoc Committee on SLE Response Criteria (Matthew H. Liang, Chair; Paul Fortin, Co-Chair; Matthias Schneider, Co-Chair, Michal Abrahamowicz, Co-Chair; Graciela S. Alarcón; James Balow; Elizabeth Benito-Garcia; Heike Bischoff; Stefano Bombardieri; Gamal Chehab; Leslie Crofford (ACR Committee on Research Liaison); Paola de Pablo; John M. Esdaile; Rebecca Fisher; Dafna Gladman; Gabor Illei; Kent Johnson; Joachim Kalden; Munther Khamashta; Takao Koike; Michael Lockshin; Susan Manzi; Joseph McCune; Alain Meyrier; Jamal Mikdashi; Andrew Moore; Marta Mosca; Michelle Petri; Charlotte Phillips; Neal Roberts, Jr; Peter Schur; Jeffrey Siegel; Josef Smolen; E. William St. Clair; Vibeke Strand. Criteria for Seroid Sparing Ability of Interventions in Systemic Lupus Erythematosus: Report of a Consensus Meeting. Arthritis Rheum 2004;50:3427-31.

Buyon JP, Petri MA; Kim MY, Kalunian K, Grossman J, Hahn BH, Merrill JT, Sammaritano L, Lockshin M, Alarcon G, Manzi S, Belmont HM, Askanase AD, Sigler L, Dooley MA, Von Feldt J, McCune WJ, Alan Friedman F, Wachs J, Cronin M, Hearth-Holmes M, Tan M, MD Licciardi F, for the SELENA Investigators. Estrogen/cyclic progesterone replacement is associated with an increased rate of mild/moderate but not severe flares in SLE. Ann Intern Med 2005; 142:953-962.

Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Elfi Moeller E, Salmon JE. Arterial stiffness in chronic inflammatory diseases. Hypertension. 2005;46:1-6.

For more publications, please see the PubMed listing.  

Research Description

Clinical Aspects of Lupus, Antiphospholipid Syndrome, and Pregnancy

Dr. Lockshin has a long-term interest in clinical aspects of systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and pregnancy in rheumatic disease patients. He is Director of the HSS unit participating in the Lupus Clinical Trials Consortium. With Dr. Melanie Harrison, and funded by the Mary Kirkland Center for Lupus Research and the National Institutes of Health, he is investigating prevalence, mechanisms, and potential treatments for cognitive dysfunction in SLE and APS. With Dr. Doruk Erkan, he participates in the Antiphospholipid Syndrome Registry (APSCORE), funded by NIH, and in a number of specific projects reflecting relative risks, outcomes, and treatments of APS. With Dr. Jane Salmon, he contributes patients to and participates in planning for an NIH-funded study of mechanisms of pregnancy loss in APS and SLE (PROMISSE), as well as in a now-completed study on atherosclerosis in SLE and rheumatoid arthritis. Dr. Lockshin also has a long-standing interest in sex differences in disease incidence; he convened a conference on this topic in 1999, participated in an Institute of Medicine review of this topic, and will convene a follow-up conference, sponsored by the Kirkland Center, in the Spring of 2006.

Clinical Trials

• PROMISSE: Predictors of Pregnancy Outcome: Biomarkers in Anti-Phospholipid Antibody Syndrome (APS) and Systemic Lupus Erythematosus (SLE)
• Cognitive Dysfunction, Diffusion Tensor Imaging and Functional Magnetic Resonance Imaging (MRI) in Antiphospholipid Antibody (aPL)-negative Systemic Lupus Erythematosus (SLE) versus aPL-positive non-SLE Patients
• Effects of Fluvastatin on Proinflammatory and Prothrombotic markers in Antiphospholipid Syndrome
• RITAPS: A Pilot Study Of Rituximab For The Anticoagulation-Resistant Manifestations Of Antiphospholipid Syndrome (APS)
• Pilot and Feasibility Study of Modafinil Treatment to Improve Cognitive Efficiency in SLE Patients
• LUNAR: A phase III, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of rituximab in subjects with class III or IV lupus nephritis